Physician profile
Egils K Bogdanovics
NPI 1619065976
$608,240.36
in general payments reported to CMS, 2019-2025
54 companies · $90K in 2025
The $90K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $60K · 2021: $63K · 2022: $112K · 2023: $107K · 2024: $77K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $74K · Travel and Lodging: $31K · Food and Beverage: $20K · Consulting Fee: $7,431 · Gift: $59.40 · Education: $56.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,928.30 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $73,536.50 |
| Travel and Lodging | $31,244.20 |
| Food and Beverage | $19,590.69 |
| Consulting Fee | $7,430.82 |
| Gift | $59.40 |
| Education | $56.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245,962.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $163,035.96 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $39,901.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36,575.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $26,870.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,726.82 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $22,325.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $15,060.97 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $8,591.45 | 2019-2025 | Synthroid |
| Mannkind Corporation | $7,480.86 | 2021-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $4,181.06 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Ascensia Diabetes Care US INC. | $3,636.26 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $2,005.75 | 2019-2024 | Farxiga, Lokelma |
| Zealand Pharma US, INC. | $1,726.99 | 2020-2022 | |
| Corcept Therapeutics | $1,096.40 | 2019-2025 | Korlym |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $695.00 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $576.71 | 2019-2025 | Tirosint, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $545.63 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $468.93 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Insulet Corporation | $384.43 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $346.82 | 2019-2022 | |
| Cequr Corporation | $326.47 | 2022-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $317.07 | 2022-2025 | Strensiq |
| Horizon Therapeutics Plc | $304.35 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $287.67 | 2024-2025 | Yorvipath |
| Beta Bionics, INC. | $280.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $279.80 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $232.99 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $197.89 | 2019-2022 | |
| Medtronic, INC. | $178.01 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Amryt Pharma Holdings Ltd | $150.04 | 2022-2023 | Mycapssa |
| Embecta Corp. | $144.67 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Medtronic Minimed, INC. | $133.45 | 2019-2020 | |
| Kyowa Kirin, INC. | $131.16 | 2022-2025 | Crysvita |
| Senseonics, Incorporated | $130.00 | 2019 | |
| Halozyme INC | $112.87 | 2023 | |
| Intra-Sana Laboratories | $100.40 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Becton, Dickinson and Company | $91.13 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $77.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $72.63 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $65.08 | 2023-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $64.48 | 2024-2025 | |
| Chiesi USA, INC. | $63.64 | 2025 | Mycapssa |
| Madrigal Pharmaceuticals | $44.69 | 2025 | Rezdiffra |
| Valeritas, INC. | $41.07 | 2019 | |
| Amarin Pharma, INC. | $39.80 | 2021 | |
| Shire North American Group INC | $39.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.78 | 2019 | |
| Grt US Holding, INC. | $24.21 | 2021 | |
| Averitas Pharma INC. | $20.86 | 2025 | Qutenza |
| Sequel Med Tech, LLC | $15.95 | 2025 | Twiist |
| Companion Medical, INC. | $15.61 | 2019 | |
| Vistapharm, INC. | $15.00 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Egils Bogdanovics listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.